上周的麻醉论系列，我们关注的话题是术中低血压事件。本周的话题，稍微宽泛了一些，但主要围绕深静脉导丝遗留问题。
[把该干的事情做好]虽然是“麻醉论”，但其实俺对危重病领域文献更熟悉。今年4月，NEJM发表了一篇重磅研究：补充谷氨酰胺不能改善危重病患者预后。这是一项重要的RCT，当时我仔细读了，琢磨可以写篇letter再来一次“云端漫步”，后来却耽搁了。到了8月11号，NEJM发表了数篇针对此研究的letter，其中一篇是做了一个meta分析图。另外一个回应，几乎就是吐槽了。不过，这段吐槽我非常喜欢。怎么说呢？
对危重病患者而言，做好最基础的事情，及早的容量复苏、抗生素使用并改善血流动力学，就能改善患者预后。那些花里胡哨的营养补充与新式疗法，都是锦上添花。还是读读下面这段吧。
Those in the field of intensive care medicine are often disappointed by trials of interventions that are initially reported as positive but that are later shown to be ineffective. The most important thing we can do to improve the outcome for our patients is to do the basic things well — for instance, by providing adequate resuscitation and antibiotics and carrying out source control in sepsis. Aside from improving patient care by conducting clinical trials, clinicians should be focusing their time and energy on improvi
[把该干的事情做好]虽然是“麻醉论”，但其实俺对危重病领域文献更熟悉。今年4月，NEJM发表了一篇重磅研究：补充谷氨酰胺不能改善危重病患者预后。这是一项重要的RCT，当时我仔细读了，琢磨可以写篇letter再来一次“云端漫步”，后来却耽搁了。到了8月11号，NEJM发表了数篇针对此研究的letter，其中一篇是做了一个meta分析图。另外一个回应，几乎就是吐槽了。不过，这段吐槽我非常喜欢。怎么说呢？
对危重病患者而言，做好最基础的事情，及早的容量复苏、抗生素使用并改善血流动力学，就能改善患者预后。那些花里胡哨的营养补充与新式疗法，都是锦上添花。还是读读下面这段吧。
Those in the field of intensive care medicine are often disappointed by trials of interventions that are initially reported as positive but that are later shown to be ineffective. The most important thing we can do to improve the outcome for our patients is to do the basic things well — for instance, by providing adequate resuscitation and antibiotics and carrying out source control in sepsis. Aside from improving patient care by conducting clinical trials, clinicians should be focusing their time and energy on improvi